MedTrace Logo

An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy

NCT00538772 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-07-11

No results posted yet for this study

Summary

Purpose:

The purpose of the correlative studies is to evaluate levels of serum factors of circulating VEGF and soluble VEGFR, circulating tumor cells and circulating endothelial cells assayed at baseline and over the course of initial treatment in order to explore relationships with baseline patient factors, measurable disease response and clinical progression.

Hypothesis soluble markers of angiogenic growth factors and receptors, and circulating endothelial and tumor cells can serve as markers for biologic activity of temsirolimus and/or sorafenib.

Conditions

  • Carcinoma, Renal Cell

Interventions

OTHER

Not applicable - blood tests/tissue specimen tests will be undertaken

Not applicable - blood tests/tissue specimen tests will be undertaken

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • Kim Chi

    lead OTHER

Principal Investigators

  • Christian Kollmannsberger, MD · BC Cancer Agency- Vancouver

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00538772 on ClinicalTrials.gov